Phase 4Recruiting
Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination (GLYCO-3P)
- Sponsor
- Nabiqasim Industries (Pvt) Ltd (Industry)
- Enrollment
- 800 planned
- Conditions
- Diabetes Mellitus; Type 2 DM
- Interventions
- Empagliflozin+Linagliptin+Metformin
- Ages
- adults, older adults
- Registry
- NCT06862739
Full record on ClinicalTrials.gov
From the registry
The efficacy and safety of a triple-pill combination therapy for advanced type 2 diabetes care. The study aims to assess the impact of 3 Oral Anti Diabetic (OAD) drugs on metabolic control, patient compliance, weight management, quality of life, diabetic treatment satisfaction and frequency of hypoglycemic events by combining them into a fixed-dose single pill.
Primary outcomes
- Changes in HbA1c levels
History
Study completion
Primary completion
Last registry update
Started
Registered